The study shows that industry-sponsored research was 33 percent more likely to find cost benefits of its drugs with threshold values between $50,000 and $150,000 compared to non-industry-sponsored research.
More than 70 percent of the 8,192 cost-effectiveness studies reported the studied drugs were more effective and costly. Among these 5,877 cost-effectiveness analyses, sponsorship bias was most heavy in drug interventions in model-based study designs.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
